MedTrace Logo

Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer

NCT07049133 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2026-01-06

No results posted yet for this study

Summary

the anti-Human Epidermal Growth Factor Receptor 2 (HER2) Trastuzumab-Deruxtecan (T-DXd) has shown impressive clinical activity in pretreated patients with metastatic breast cancer (MBC) but is also associated with a non-negligible rate of adverse events that may lead to treatment discontinuation and/or the onset of pneumonitis/interstitial lung disease (ILD)

The aim of the study is to identify and describe potentially predictive markers related to the onset of relevant T-DXd-related toxicities

Conditions

Interventions

OTHER

T-DXd toxicity marker identification

to find potential predictive markers associated with T-DXd-related toxicities

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Elisabetta Munzone, MD · European Institute of Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07049133 on ClinicalTrials.gov